Pan F - Search Results

1

Modeling Clinical Outcomes in Prostate Cancer: Application and Validation of the Discrete Event Simulation Approach.

Pan F, Reifsnider O, Zheng Y, Proskorovsky I, Li T, He J, Sorensen SV. Pan F, et al. Value Health. 2018 Apr;21(4):416-422. doi: 10.1016/j.jval.2017.09.022. Epub 2017 Nov 27. Value Health. 2018. PMID: 29680098 Free article.

2

Modeling Treatment Sequences in Pharmacoeconomic Models.

Zheng Y, Pan F, Sorensen S. Zheng Y, et al. Among authors: pan f. Pharmacoeconomics. 2017 Jan;35(1):15-24. doi: 10.1007/s40273-016-0455-3. Pharmacoeconomics. 2017. PMID: 27722894

3

Systematic Review of Relapsed or Refractory Mantle Cell Lymphoma (MCL) Clinical Trials: Implications for Decision Modeling.

Sorensen S, Dorman E, Xu Y, Sallum R, Pan F, Szatkowski A, Gaudig M, Sengupta N. Sorensen S, et al. Among authors: pan f. Value Health. 2014 Nov;17(7):A615-6. doi: 10.1016/j.jval.2014.08.2168. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202152 Free article. No abstract available.

4

Simulation Model of Ibrutinib for Chronic Lymphocytic Leukemia (CLL) With Prior Treatment.

Pan F, Peng S, Sorensen S, Dorman E, Sun S, Gaudig M, Sengupta N. Pan F, et al. Value Health. 2014 Nov;17(7):A620-1. doi: 10.1016/j.jval.2014.08.2198. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202182 Free article. No abstract available.

5

Incidence-based cost-of-illness model for metastatic breast cancer in the United States.

Sorensen SV, Goh JW, Pan F, Chen C, Yardley D, Martín M, Knopf K, Benedict A, Giorgetti C, Iyer S. Sorensen SV, et al. Among authors: pan f. Int J Technol Assess Health Care. 2012 Jan;28(1):12-21. doi: 10.1017/S026646231100064X. Int J Technol Assess Health Care. 2012. PMID: 22617734

6

Simulation Model of Ibrutinib in Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL).

Peng S, Sorensen S, Pan F, Dorman E, Sun S, Van Sanden S, Sengupta N, Gaudig M. Peng S, et al. Among authors: pan f. Value Health. 2014 Nov;17(7):A620. doi: 10.1016/j.jval.2014.08.2196. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202180 Free article. No abstract available.

7

Approach to fixing the discrepancy found in the Wu et al. FACT-P to EQ-5D questionnaire mapping algorithm.

Cella D, Proskorovsky I, Pan F. Cella D, et al. Among authors: pan f. Value Health. 2012 Jul-Aug;15(5):783-4; author reply 785. doi: 10.1016/j.jval.2012.01.011. Epub 2012 Jun 15. Value Health. 2012. PMID: 22867790 Free article. No abstract available.

8

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.

Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR. Kansal AR, et al. Among authors: pan f. Heart. 2012 Apr;98(7):573-8. doi: 10.1136/heartjnl-2011-300646. Heart. 2012. PMID: 22422743 Free PMC article. Clinical Trial.

9

Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.

Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R. Pan F, et al. Value Health. 2011 Jul-Aug;14(5):652-6. doi: 10.1016/j.jval.2011.01.006. Epub 2011 Jun 2. Value Health. 2011. PMID: 21839402 Free article. Clinical Trial.

10

Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.

Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E. Pan F, et al. Clin Ther. 2010 Dec;32(14):2444-56. doi: 10.1016/j.clinthera.2010.12.003. Clin Ther. 2010. PMID: 21353113

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,143 results

Search Page

Filters